Literature DB >> 21871523

Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to Kava Kava.

Mamta Behl1, Abraham Nyska, Rajendra S Chhabra, Gregory S Travlos, Laurene M Fomby, Barney R Sparrow, Milton R Hejtmancik, Po C Chan.   

Abstract

Kava Kava is an herbal supplement used as an alternative to antianxiety drugs. Although some reports suggest an association of Kava Kava with hepatotoxicity , it continues to be used in the United States due to lack of toxicity characterization. In these studies F344/N rats and B6C3F1 mice were administered Kava Kava extract orally by gavage in corn oil for two weeks, thirteen weeks or two years. Results from prechronic studies administered Kava Kava at 0.125 to 2g/kg body weight revealed dose-related increases in liver weights and incidences of hepatocellular hypertrophy. In the chronic studies, there were dose-related increases in the incidences of hepatocellular hypertrophy in rats and mice administered Kava Kava for up to 1g/kg body weight. This was accompanied by significant increases in incidences of centrilobular fatty change. There was no treatment- related increase in carcinogenic activity in the livers of male or female rats in the chronic studies. Male mice showed a significant dose-related increase in the incidence of hepatoblastomas. In female mice, there was a significant increase in the combined incidence of hepatocellular adenoma and carcinoma in the low and mid dose groups but not in the high dose group. These findings were accompanied by several nonneoplastic hepatic lesions. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21871523      PMCID: PMC3190036          DOI: 10.1016/j.fct.2011.07.067

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  68 in total

1.  Safety concerns about kava not unique.

Authors:  Peter A G M De Smet
Journal:  Lancet       Date:  2002-10-26       Impact factor: 79.321

2.  Kava: a test case for Canada's new approach to natural health products.

Authors:  Heather S Boon; Albert H C Wong
Journal:  CMAJ       Date:  2003-11-25       Impact factor: 8.262

3.  Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.

Authors:  S Wanwimolruk; S Bhawan; P F Coville; S C Chalcroft
Journal:  Eur J Clin Pharmacol       Date:  1998-07       Impact factor: 2.953

4.  Inhibition of human cytochrome P450 activities by kava extract and kavalactones.

Authors:  James M Mathews; Amy S Etheridge; Sherry R Black
Journal:  Drug Metab Dispos       Date:  2002-11       Impact factor: 3.922

5.  [Fulminant liver failure after administration of the herbal antidepressant Kava-Kava].

Authors:  M Kraft; T W Spahn; J Menzel; N Senninger; K H Dietl; H Herbst; W Domschke; M M Lerch
Journal:  Dtsch Med Wochenschr       Date:  2001-09-07       Impact factor: 0.628

Review 6.  Kava--the unfolding story: report on a work-in-progress.

Authors:  Alison Denham; Michael McIntyre; Julie Whitehouse
Journal:  J Altern Complement Med       Date:  2002-06       Impact factor: 2.579

Review 7.  Kava extracts: safety and risks including rare hepatotoxicity.

Authors:  R Teschke; W Gaus; D Loew
Journal:  Phytomedicine       Date:  2003       Impact factor: 5.340

8.  Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases.

Authors:  Rolf Teschke; Alexander Schwarzenboeck; Karl-Heinz Hennermann
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-12       Impact factor: 2.566

Review 9.  Kava extract for treating anxiety.

Authors:  M H Pittler; E Ernst
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 10.  Kava: an overview.

Authors:  Y N Singh
Journal:  J Ethnopharmacol       Date:  1992-08       Impact factor: 4.360

View more
  5 in total

1.  Ex vivo and in vitro inhibitory potential of Kava extract on monoamine oxidase B activity in mice.

Authors:  Bárbara Nunes Krum; Catiuscia Molz de Freitas; Alcindo Busanello; Larissa Finger Schaffer; Roselei Fachinetto
Journal:  J Tradit Complement Med       Date:  2021-07-14

2.  Effect of quercetin against lindane induced alterations in the serum and hepatic tissue lipids in wistar rats.

Authors:  Viswanadha Vijaya Padma; Gurusamy Lalitha; Nicholson Puthanveedu Shirony; Rathinasamy Baskaran
Journal:  Asian Pac J Trop Biomed       Date:  2012-11

3.  Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster).

Authors:  Amanda C Martin; Ed Johnston; Chengguo Xing; Adrian D Hegeman
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

Review 4.  Hepatotoxicity Induced by "the 3Ks": Kava, Kratom and Khat.

Authors:  Flaminia Pantano; Roberta Tittarelli; Giulio Mannocchi; Simona Zaami; Serafino Ricci; Raffaele Giorgetti; Daniela Terranova; Francesco P Busardò; Enrico Marinelli
Journal:  Int J Mol Sci       Date:  2016-04-16       Impact factor: 5.923

Review 5.  The toxicologic pathology aspects of selected natural herbal products and related compounds.

Authors:  Ruba Ibrahim; Abraham Nyska; June Dunnick; Yuval Ramot
Journal:  J Toxicol Pathol       Date:  2021-03-29       Impact factor: 1.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.